Amyloidosis

6 trials 1 recruiting MedDRA PT
6 Registered trials
1 Recruiting
4 Unique sponsors
6 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
H Endocrinology (ATC H) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Corticosteroid 2 substances
Unknown / small molecule 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (chimeric) 1 substance
IMiD 1 substance
Phase II: 2 Phase I (Other): 1 Other: 2 Other: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

2 trials
  • European Myeloma Network B.V. Academic
    BELANTAMAB MAFODOTIN
    2024-513075-40-00 5 countries 2021 n=33
    Ended
  • Intergroupe Francophone Du Myelome Academic
    DEXAMETHASONE; DEXAMETHASONE ACETATE; ISATUXIMAB; POMALIDOMIDE
    2024-513887-25-00 1 country n=30
    Ended

Phase I (Other)

1 trial
  • Pfizer Inc. Commercial
    TAFAMIDIS
    2023-509241-12-00 1 country 2024 n=12 Orphan
    Ended

Other

2 trials
  • Pfizer Inc. Commercial
    IMP not specified
    2024-514166-40-00 1 country 2024 n=22
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2026-525342-29-00 1 country 2026 n=24
    Ended

Other

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-503429-20-00 3 countries 2024 n=16
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 3 Other, Phase I (Other) 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Other 1
European Myeloma Network B.V. Academic 1 Phase II 0
Intergroupe Francophone Du Myelome Academic 1 Phase II 0
New trials by year
2021
1
2024
3
2026
1
← All indication landscapes